Dr. Pouliot obtained doctorates in medicine (M.D.) and in Physiology-Endocrinology (Ph.D.) from Laval University. After completing a residency in Urology (F.R.C.S.C.), he did a post-doctoral fellowship in Urologic Oncology and molecular imaging at the University of California, Los Angeles (UCLA). Since 2010, he has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an associate professor in Laval University’s Department of surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high risk, advanced and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography (PET) with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404).  He is also involved in the development of new radioligand therapeutics.

His research program has four aims: 1) To develop a dynamic imaging method based on a transcriptional amplification system allowing the sensitive detection of a luminescent reporter gene under the control of prostate cancer specific promoters. This microscopy method will allow predicting the patient’s response to antiandrogen treatments. 2) Use positron emission tomography imaging (PET/CT) as a quantitative method to identify the very high risk prostate cancer and to assess metastasis individual response, in addition to global response to systemic treatment. 3) Develop a prostate cancer immunotherapy based on a transcriptional amplification system specific to prostate cancer. This vaccine vector will allow the introduction of recombinant genes in patient’s prostate cancer cells to induce an efficient immune response against cancer cells.  4) Characterize the androgen receptor (AR) activation in castration resistant prostate cancer patients. This project aims to determine which steroids activate the AR under chemical castration and to identify new AR interacting partners using proteomics.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67694

Latest news

133 entries « ‹ 2 of 14 › »

Kokorovic A, So AI, Serag H, French C, Hamilton RJ, Izard JP, Nayak JG, Pouliot F, Saad F, Shayegan B, Aprikian A, Rendon RA

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes

Journal Article

Can Urol Assoc J, 16 (8), 2022.

| Links:

Bedke J, Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Soulières D, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Tamada S, Nguyen AM, Wan S, Perini RF, Rhoda Molife L, Atkins MB, Powles T

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Journal Article

Eur Urol, 82 (4), 2022.

Abstract | Links:

Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Kollmannsberger C, Heng D, Wood LA, Castonguay V, Soulières D, Winquist E, Canil C, Graham J, Bjarnason GA, Breau RH, Pouliot F, Swaminath A

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Journal Article

Adv Radiat Oncol, 7 (4), 2022.

Abstract | Links:

Chabaud S, Pellerin È, Caneparo C, Ringuette-Goulet C, Pouliot F, Bolduc S

Bladder cancer cell lines adapt their aggressiveness profile to oxygen tension

Journal Article

Oncol Lett, 24 (1), 2022.

Abstract | Links:

Millan B, Breau RH, Bhindi B, Mallick R, Tanguay S, Finelli A, Lavallée LT, Pouliot F, Rendon R, So AI, Dean L, Lattouf JB, Basappa NS, Kapoor A

A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System

Journal Article

J Urol, 208 (4), 2022.

Abstract | Links:

Turcotte B, Bélanger L, Blais AS, Blouin AC, Bolduc S, Bolduc-Mokhtar A, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Gaudreau N, Lacombe L, Moore K, Morin F, Nadeau G, Paquet S, Simard F, Simonyan D, Soucy F, Tiguert R, Toren P, Lodde M, Pouliot F

Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective

Journal Article

Can Urol Assoc J, 16 (10), 2022.

Abstract | Links:

Frégeau-Proulx L, Lacouture A, Berthiaume L, Weidmann C, Harvey M, Gonthier K, Pelletier JF, Neveu B, Jobin C, Bastien D, Bergeron A, Fradet Y, Lacombe L, Laverdière I, Atallah C, Pouliot F, Audet-Walsh É

Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

Journal Article

Mol Metab, 62 , 2022.

Abstract | Links:

Kim SSY, Breau R, Mallick R, Kapoor A, Finelli A, Pouliot F, Tanguay S, Fairey A, Bhindi B, Lavallee L, So A, Rendon R

Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort

Journal Article

Urology, 165 , 2022.

Abstract | Links:

Zheng J, Sampurno F, George DJ, Morgans AK, Nguyen H, Abrahm JL, Bjartell A, Davis ID, Fitch MI, Gillessen S, Kanesvaran R, Matthew A, Millar JL, O'Sullivan JM, Payne H, Pouliot F, Yates P, Evans SM

Establishing metastatic prostate cancer quality indicators using a modified Delphi approach

Journal Article

Clin Genitourin Cancer, 20 (2), 2022.

Abstract | Links:

Richard PO, Violette PD, Bhindi B, Breau RH, Kassouf W, Lavallée LT, Jewett M, Kachura JR, Kapoor A, Noel-Lamy M, Ordon M, Pautler SE, Pouliot F, So AI, Rendon RA, Tanguay S, Collins C, Kandi M, Shayegan B, Weller A, Finelli A, Kokorovic A, Nayak J

Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations

Journal Article

Can Urol Assoc J, 16 (2), 2022.

| Links:

133 entries « ‹ 2 of 14 › »
Signaler des ajouts ou des modifications

Active projects

  • Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2023-12-15
  • National Program on Radioligand Therapy for Prostate Cancer, from 2018-01-01 to 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2023-06-30
  • Surveillance of Complex Renal Cysts: The SOCRATIC study, from 2019-10-01 to 2028-09-30
  • Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
  • Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities, from 2022-10-01 to 2027-09-30
  • Utilisation de l’imagerie moléculaire par microscopie à bioluminescence ou par tomographie par émission de positrons afin d’optimiser les stratégies thérapeutiques des patients atteints de cancers urologiques, from 2019-07-01 to 2023-06-30

Recently finished projects

  • A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease , from 2021-04-01 to 2022-03-31
  • Bourse Concert pour la vie , from 2020-11-13 to 2021-11-12
  • CUASF-BCC Research Grant Program , from 2020-06-06 to 2021-06-05
  • Projet de recherche sur le cancer de la prostate intitulé Ironman , from 2020-03-24 to 2021-03-23
Data provided by the Université Laval research projects registery